130 related articles for article (PubMed ID: 12691044)
1. Comparing liver toxicity between efavirenz and nevirapine.
TreatmentUpdate; 2002 Feb; 14(2):7-8. PubMed ID: 12691044
[No Abstract] [Full Text] [Related]
2. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
[TBL] [Abstract][Full Text] [Related]
3. [Efavirenz--comprehensive status of studies].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
[No Abstract] [Full Text] [Related]
4. Switching from protease inhibitors to the non-nuke efavirenz.
TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
[No Abstract] [Full Text] [Related]
5. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
6. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
Soriano V; Dona C; Barreiro P; González-Lahoz J
AIDS; 2000 Jul; 14(11):1672-3. PubMed ID: 10983663
[No Abstract] [Full Text] [Related]
7. NNRTI hepatotoxicity: efavirenz versus nevirapine.
Pulido F; Torralba M
J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
[No Abstract] [Full Text] [Related]
8. An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.
Manfredi R; Calza L; Chiodo F
J Acquir Immune Defic Syndr; 2005 Feb; 38(2):236-8. PubMed ID: 15671811
[No Abstract] [Full Text] [Related]
9. [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-20. PubMed ID: 15373038
[No Abstract] [Full Text] [Related]
10. Nevirapine found to be as effective as efavirenz.
TreatmentUpdate; 2003; 15(2):3-4. PubMed ID: 12693360
[No Abstract] [Full Text] [Related]
11. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV agents. Efavirenz versus indinavir: who really wins?
TreatmentUpdate; 2000 Feb; 12(1):4-5. PubMed ID: 12125628
[No Abstract] [Full Text] [Related]
13. Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors.
Arranz-Caso JA; Gorgolas M; Estrada V; García-Diaz JD
HIV Med; 2004 Mar; 5(2):128-9. PubMed ID: 15012654
[No Abstract] [Full Text] [Related]
14. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
Ena J; Amador C; Benito C; Fenoll V; Pasquau F
Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
Zhou J; Phanupak P; Kiertiburanakul S; Ditangco R; Kamarulzaman A; Pujary S;
J Acquir Immune Defic Syndr; 2006 Dec; 43(4):501-3. PubMed ID: 17099317
[No Abstract] [Full Text] [Related]
16. Long-term safety and efficacy of NNRTI within the central nervous system.
von Giesen HJ; Köller H; de Nocker D; Haslinger BA; Arendt G
HIV Clin Trials; 2003; 4(6):382-90. PubMed ID: 14628281
[TBL] [Abstract][Full Text] [Related]
17. Non-nucleoside reverse transcriptase inhibitors--an overview.
Bell C; Matthews GV; Nelson MR
Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
[No Abstract] [Full Text] [Related]
18. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
[TBL] [Abstract][Full Text] [Related]
19. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz.
Caso JA; Prieto Jde M; Casas E; Sanz J
AIDS; 2001 Jul; 15(11):1447-8. PubMed ID: 11504970
[No Abstract] [Full Text] [Related]
20. The tolerability of efavirenz after nevirapine-related adverse events.
Clarke S; Harrington P; Barry M; Mulcahy F
Clin Infect Dis; 2000 Sep; 31(3):806-7. PubMed ID: 11017835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
